Clinical Trials

47 results for Kidney/Renal Cancer


A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma

  • Condition: Renal Cell Carcinoma
  • Intervention: Device: CyberKnife
  • Study ID: NCT01890590
View Trial

Star-tor - Registry For The Evaluation Of The Safety, Tolerability And Efficacy Of Temsirolimus (Torisel®), Sunitinib (Sutent®), And Axitnib (Inlyta®) For The Treatment Of Subjects With Advanced Renal Cell Carcinoma (Mrcc), Mantle Cell Lymphoma (Mcl), And

  • Condition: Carcinoma, Renal Cell, Advanced, Lymphoma, Mantle-Cell, Gastrointestinal Stroma Tumors
  • Intervention: Drug: Temsirolimus, Drug: Temsirolimus, Drug: Sunitinib, Drug: Sunitinib, Drug: Axitinib
  • Study ID: NCT00700258
View Trial

Axitinib In Advanced / Metastatic Renal Cell Carcinoma - A Non-interventional Study Of Real World Treatment Outcomes In Patients Receiving 2nd Line Axitinib After 1st Line Sunitinib (Adonis)

  • Condition: Metastatic Renal Cell Carcinoma (mRCC)
  • Intervention: Other: observational
  • Study ID: NCT02184416
View Trial

A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients With Advanced Solid Tumors

  • Condition: Adult Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Cancer, Recurrent Colorectal Carcinoma, Recurrent Melanoma, Recurrent Ovarian Carcinoma, Recurrent Renal Cell Carcinoma, Stage IV Ovarian Cancer, Stage IVA Colorectal Cancer, Stage
  • Intervention: Other: Laboratory Biomarker Analysis, Biological: Pembrolizumab, Biological: Ziv-Aflibercept
  • Study ID: NCT02298959
View Trial

Concurrent Chemoradiation With or Without DC-CIK Immunotherapy in Treating Locally Advanced Esophageal Cancer

  • Condition: Esophageal Carcinoma
  • Intervention: Other: concurrent chemoradiotherapy plus DC-CIK immunotherapy, Other: Concurrent chemoradiation only
  • Study ID: NCT01691625
View Trial

177Lu-PP-F11N for Receptor Targeted Therapy and Imaging (Theranostics) of Metastatic Medullary Thyroid Cancer - a Pilot and a Phase I Study.

  • Condition: Thyroid Cancer, Medullary
  • Intervention: Drug: 177Lu-PP-F11N
  • Study ID: NCT02088645
View Trial

An Open-label, Phase II, Registry Study of Lutetium-177 [DOTA0, Tyr3] Octreotate (Lu-DOTA-TATE) Treatment in Subjects With Somatostatin Receptor Positive Tumours

  • Condition: Carcinoma, Neuroendocrine
  • Intervention: Other: Lu-DOTA-TATE radiopharmaceutical
  • Study ID: NCT01876771
View Trial

Predictors of Response to Neoadjuvant Docetaxel-Carboplatin Chemotherapy for Patients With Stage II and III Triple Negative Breast Cancer

  • Condition: Breast Cancer, Breast Cancer Stage II-III
  • Intervention: Drug: Docetaxel- Carboplatin
  • Study ID: NCT01560663
View Trial

Hematopoietic Stem Cell Transplant for Sickle Cell Disease

  • Condition: Sickle Cell Disease, Sickle Cell Anemia, SCD
  • Intervention: Drug: Fludarabine, Procedure: Hematopoietic Stem Cell Transplant (HSCT)
  • Study ID: NCT02065596
View Trial

A Randomized Phase II Study to Evaluate the Efficacy and Safety of Chemotherapy (CT) vs Androgen Deprivation Therapy (ADT) in Patients With Recurrent and/or Metastatic, Androgen Receptor (AR) Expressing, Salivary Gland Cancer (SGCs)

  • Condition: Salivary Gland Cancer
  • Intervention: Drug: bicalutamide + triptorelin, Drug: Cisplatin + Doxorubicin, Drug: Carboplatin + Paclitaxel
  • Study ID: NCT01969578
View Trial

Phase Ib Trial Of Pembrolizumab And Nintedanib

  • Condition: Patients With Any Advanced Solid Tumors.
  • Intervention: Drug: Nintedanib, Drug: Pembrolizumab
  • Study ID: NCT02856425
View Trial

A National, Prospective, Non-Interventional Study (NIS) of Nivolumab (BMS-936558) in Patients With Advanced Renal Cell Carcinoma After Prior Therapy

  • Condition: Renal Cell Carcinoma
  • Intervention: Other: Non Interventional
  • Study ID: NCT02940639
View Trial

Phase I/II Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA)

  • Condition: Renal Cell Carcinoma
  • Intervention: Drug: Sunitinib, Drug: Bevacizumab
  • Study ID: NCT02919371
View Trial

A First-in-Human, Open-label, Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancers

  • Condition: Neoplasms
  • Intervention: Drug: JNJ-63723283
  • Study ID: NCT02908906
View Trial

Kidney Cancer DNA Registry

  • Condition: Renal Cancer
  • Intervention: Other: salvia for germline DNA, Behavioral: the Kidney Cancer Questionnaire, Behavioral: Family History Questionnaire (when applicable)
  • Study ID: NCT02087852
View Trial

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

  • Condition: Urothelial Carcinoma, Renal Cell Carcinoma
  • Intervention: Drug: cabozantinib, Drug: atezolizumab, Drug: cabozantinib
  • Study ID: NCT03170960
View Trial

Cabosun II: Cabozantinib Versus Sunitinib for Metastatic Variant Histology Renal Cell Carcinoma

  • Condition: Malignant Neoplasms of Urinary Tract, Renal Cell Carcinoma
  • Intervention: Drug: Cabozantinib, Drug: Sunitinib
  • Study ID: NCT03541902
View Trial

Prospective Non Interventional Study of Cabozantinib Tablets in Adults With Advanced Renal Cell Carcinoma Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy

  • Condition: Renal Cell Carcinoma
  • Intervention: Other: Data collection
  • Study ID: NCT03419572
View Trial

A Phase 2 Open-Label Study of Nivolumab Combined With Cabozantinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (CA209-9KU)

  • Condition: Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma
  • Intervention: Drug: cabozantinib, Drug: nivolumab
  • Study ID: NCT03635892
View Trial

Prospective Non-interventional Study of Cabozantinib in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment

  • Condition: Advanced or Metastatic Renal Cell Carcinoma
  • Study ID: NCT03647878
View Trial

A Phase 2 Trial of PT2977 in Combination With Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

  • Condition: RCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer, Renal Cancer, Renal Cell Carcinoma, Renal Cell Cancer Metastatic, Renal Cell Carcinoma Recurrent, Renal Cell Cancer, Recurrent, Kidney
  • Intervention: Drug: PT2977 in combination with cabozantinib tablets
  • Study ID: NCT03634540
View Trial

Preventive Effects of Low-dose Aspirin as Adjuvant Therapy After Radical Nephrectomy on Disease Recurrence/Metastasis and Survival in Patients With Locally Advanced Renal Cell Carcinoma: an Observational Prospective Cohort Study

  • Condition: Aspirin as Adjuvant Therapy in Patients With Surgically Treated High Risk Renal Cell Carcinoma
  • Intervention: Drug: Low dose of aspirin
  • Study ID: NCT03734614
View Trial

BIOREN (Predictive BIOmarkers in Metastatic RENal Cancer) - A Translational Study on Immunotherapy for Metastatic Renal Cancer

  • Condition: Renal Cancer Metastatic
  • Intervention: Biological: Immunological and tumour characterization
  • Study ID: NCT03628859
View Trial

Development and Evaluation of High Risk Group Prediction Model in T1 Stage Renal Cell Cancer Using Molecular Biomarkers

  • Condition: Clear Renal Cell Cancer (< 7cm Size)
  • Intervention: Procedure: Partial or radical nephrectomy
  • Study ID: NCT03694912
View Trial

Phase II Study: Stereotactic Ablative Radiotherapy for Renal Tumors

  • Condition: Renal Tumor
  • Intervention: Radiation: Stereotactic Ablative Radiotherapy
  • Study ID: NCT03747133
View Trial

Phase II Trial of AZD6738 Alone and in Combination With Olaparib in Patients With Selected Solid Tumor Malignancies

  • Condition: Clear Cell Renal Cell Carcinoma, Locally Advance Pancreatic Ductal Adenocarcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Renal Cell Carcinoma, Metastatic Urothelial Carcinoma, Pancreatic Ductal Ad
  • Intervention: Drug: ATR Kinase Inhibitor AZD6738, Drug: Olaparib
  • Study ID: NCT03682289
View Trial

A Phase I Open Label, Safety And Preliminary Efficacy Study of MRx0518 In Combination With Pembrolizumab In Patients With Advanced Malignancies Who Have Progressed On PD-1 Inhibitors

  • Condition: Oncology, Solid Tumor, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma, Bladder Cancer
  • Intervention: Drug: MRx0518, Drug: Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
  • Study ID: NCT03637803
View Trial

A Prospective, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial Evaluating the Use of Perioperative Intravenous Lidocaine Infusion to Decrease Pain Scores and Opioid Consumption After Robotic-Assisted Prostatectomy and Robotic-Assisted Partia

  • Condition: Kidney Cancer, Prostate Cancer
  • Intervention: Drug: Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution, Drug: 0.9% Sodium Chloride Injection
  • Study ID: NCT03824808
View Trial

Molecular Analysis for Therapy Choice (MATCH)

  • Condition: Advanced Malignant Neoplasm, Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Plasma Cell Myeloma, Refractory Malignant Neoplasm, Refractory Plasma Cell Myeloma
  • Intervention: Drug: Afatinib, Drug: Akt inhibitor AZD5363, Drug: Binimetinib, Drug: Crizotinib, Other: Cytology Specimen Collection Procedure, Drug: Dabrafenib, Drug: Dasatinib, Drug: Defactinib, Drug: FGFR Inhibitor AZD4547, Other: Laboratory Biomarker Analysis, Biological: Nivolumab, Drug: Osimertinib, Drug: Palbociclib, Biological: Pertuzumab, Drug: PI3K-beta Inhibitor GSK2636771, Drug: Sapanisertib, Drug: Sunitinib Malate, Drug: Taselisib, Drug: Trametinib, Biological: Trastuzumab Emtansine, Drug: Trk Inhibitor LOXO-101, Drug: Vismodegib, Drug: WEE1 Inhibitor AZD1775
  • Study ID: NCT02465060
View Trial

FASTERCC: Folic Acid Supplement Versus Placebo for Treating Mucositis Adverse Events in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapy. A Randomized, Double-blind Trial From the Danish Renal Cancer Group (DARENCA Study-4)

  • Condition: Mucositis
  • Intervention: Drug: Folic Acid, Drug: Placebo Oral Tablet
  • Study ID: NCT03581773
View Trial

A Phase III Study Testing the Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic Renal Cell Carcinoma Treated With Sunitinib

  • Condition: Renal Cell Carcinoma, Metastatic, Renal Cell Cancer, Recurrent
  • Intervention: Behavioral: Concomitant coaching
  • Study ID: NCT03013946
View Trial

An International Investigator-led Phase III Multi Arm Multi Stage Multi-centre Randomised Controlled Platform Trial of Adjuvant Therapy in Patients With Resected Primary Renal Cell Carcinoma (RCC) at High or Intermediate Risk of Relapse

  • Condition: Renal Cell Carcinoma
  • Intervention: Drug: Durvalumab, Drug: Tremelimumab
  • Study ID: NCT03288532
View Trial

A Phase 2 Study of Neoadjuvant Cabozantinib in Patients With Locally Advanced Non-Metastatic Clear Cell Renal Cell Carcinoma

  • Condition: Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8
  • Intervention: Drug: Cabozantinib
  • Study ID: NCT04022343
View Trial

Talazoparib and Avelumab in Genomically Defined Metastatic Renal Cell Carcinoma

  • Condition: Metastatic Renal Cell Carcinoma, Advanced Retinal Disease Carcinoma
  • Intervention: Drug: Talazoparib, Drug: Avelumab
  • Study ID: NCT04068831
View Trial

Cabozantinib in Adult Patients With Advanced Renal Cell Carcinoma Following Prior Systemic Check Point Inhibition Therapy: a Retrospective, Non-interventional Study

  • Condition: Advanced Renal Cell Carcinoma (All Subtypes), Metastatic Renal Cell Carcinoma (All Subtypes)
  • Intervention: Other: Documentation
  • Study ID: NCT04147143
View Trial

A Phase I Trial of Interleukin-2 (Aldesleukin) and Pembrolizumab Combination Therapy for Patients With Advanced Renal Cell Carcinoma

  • Condition: Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
  • Intervention: Biological: Aldesleukin, Biological: Pembrolizumab
  • Study ID: NCT03260504
View Trial

Monitoring of Treatment Related Toxicities From Oral Targeted Agents and Immunotherapy Among Patients With Advanced Renal Cell Carcinoma (RCC) Using Carevive Software, a Single-Arm Phase II Feasibility Study

  • Condition: Advanced Renal Cell Carcinoma
  • Intervention: Other: Carevive software
  • Study ID: NCT03229083
View Trial

Genetic Evaluation of Renal Cell Carcinoma; Predicting Biomarkers for Renal Cell Carcinoma

  • Condition: Kidney Cancer
  • Study ID: NCT03414827
View Trial

Phase II Clinical Study of PD-1 Monoclonal Antibody Combination With Autologous Cytokine-induced Killer Cell Immunotherapy in the Second-line Treatment of Metastatic Clear Cell Renal Cell Carcinoma

  • Condition: Metastic Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Second-line Treatment
  • Intervention: Biological: SHR-1210, Biological: CIK cells
  • Study ID: NCT03987698
View Trial

Phase I/II Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma

  • Condition: Renal Cell Carcinoma
  • Intervention: Drug: Nivolumab, Drug: Axitinib
  • Study ID: NCT03172754
View Trial

Phase II Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma. HCRN: GU16-260

  • Condition: Advanced Renal Cell Carcinoma
  • Intervention: Drug: Nivolumab 240 mg, Drug: Ipilimumab 1mg/kg, Drug: Nivolumab 3mg/kg, Drug: Nivolumab 360mg
  • Study ID: NCT03117309
View Trial

Cytoreductive Stereotactic Hypofractionated Radiotherapy With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer

  • Condition: Metastatic Renal Cell Carcinoma
  • Intervention: Drug: Ipilimumab/ Nivolumab, Radiation: SBRT + Ipilimumab/Nivolumab
  • Study ID: NCT04090710
View Trial

REPLICA: Real Patient Life Treatment With Cabozantinib in Patients With Advanced or Metastatic RCC: A Descriptive and Prospective Non-Interventional Study

  • Condition: Advanced or Metastatic Renal Cell Carcinoma
  • Study ID: NCT04106349
View Trial

A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Advanced Renal Cell Carcinoma With Bone Metastasis (RadiCal)

  • Condition: Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Collecting Duct Carcinoma, Kidney Medullary Carcinoma, Metastatic Malignant Neoplasm in the Bone, Papillary Renal Cell Carcinoma, Stage IV Renal Cell
  • Intervention: Drug: Cabozantinib, Drug: Cabozantinib S-malate, Other: Quality-of-Life Assessment, Other: Questionnaire Administration, Radiation: Radium Ra 223 Dichloride
  • Study ID: NCT04071223
View Trial

A Phase 2, Single-arm Open-label Study of Combination Nivolumab and Ipilimumab Retreatment in Advanced Renal Cell Carcinoma Patients Progressing on Nivolumab Maintenance Therapy After Nivolumab and Ipilimumab Induction

  • Condition: Renal Cell Carcinoma
  • Intervention: Biological: Nivolumab, Biological: Ipilimumab
  • Study ID: NCT04088500
View Trial

A Phase III, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination With Cabozantinib Versus Cabozantinib Alone in Patients With Inoperable, Locally Advanced, or Metastatic Renal Cell Carcinoma W

  • Condition: Carcinoma, Renal Cell
  • Study ID: NCT04338269
View Trial

A Phase 1/1b Study of Sitravatinib in Combination With Nivolumab and Ipilimumab in Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies

  • Condition: Clear-Cell Renal Cell Carcinoma
  • Study ID: NCT04518046
View Trial